Arcutis Biotherapeutics (ARQT) Competitors $14.19 -0.58 (-3.93%) Closing price 08/11/2025 04:00 PM EasternExtended Trading$14.36 +0.17 (+1.20%) As of 08:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARQT vs. RYTM, NUVL, TGTX, AXSM, LNTH, CRSP, ADMA, ABVX, MRUS, and KRYSShould you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Rhythm Pharmaceuticals (RYTM), Nuvalent (NUVL), TG Therapeutics (TGTX), Axsome Therapeutics (AXSM), Lantheus (LNTH), CRISPR Therapeutics (CRSP), ADMA Biologics (ADMA), Abivax (ABVX), Merus (MRUS), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Arcutis Biotherapeutics vs. Its Competitors Rhythm Pharmaceuticals Nuvalent TG Therapeutics Axsome Therapeutics Lantheus CRISPR Therapeutics ADMA Biologics Abivax Merus Krystal Biotech Rhythm Pharmaceuticals (NASDAQ:RYTM) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk. Do analysts prefer RYTM or ARQT? Rhythm Pharmaceuticals presently has a consensus price target of $101.57, suggesting a potential upside of 7.70%. Arcutis Biotherapeutics has a consensus price target of $19.80, suggesting a potential upside of 39.53%. Given Arcutis Biotherapeutics' higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Is RYTM or ARQT more profitable? Arcutis Biotherapeutics has a net margin of -35.40% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Arcutis Biotherapeutics' return on equity of -62.62% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-117.13% -1,831.43% -48.33% Arcutis Biotherapeutics -35.40%-62.62%-25.16% Does the media prefer RYTM or ARQT? In the previous week, Arcutis Biotherapeutics had 11 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 32 mentions for Arcutis Biotherapeutics and 21 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.74 beat Arcutis Biotherapeutics' score of 0.63 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Arcutis Biotherapeutics 11 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, RYTM or ARQT? Arcutis Biotherapeutics has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M48.14-$260.60M-$3.01-31.33Arcutis Biotherapeutics$196.54M8.66-$140.04M-$0.75-18.92 Which has more volatility and risk, RYTM or ARQT? Rhythm Pharmaceuticals has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. SummaryArcutis Biotherapeutics beats Rhythm Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARQT vs. The Competition Export to ExcelMetricArcutis BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.77B$3.00B$5.48B$9.72BDividend YieldN/A2.28%4.59%4.13%P/E Ratio-18.9217.0529.7724.63Price / Sales8.66347.15455.03102.60Price / CashN/A40.7324.8127.99Price / Book10.518.898.595.76Net Income-$140.04M-$54.75M$3.26B$264.95M7 Day Performance-7.38%-2.71%-0.33%-0.01%1 Month Performance-5.46%4.43%2.12%1.27%1 Year Performance49.53%19.64%44.65%26.11% Arcutis Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARQTArcutis Biotherapeutics2.703 of 5 stars$14.19-3.9%$19.80+39.5%+46.1%$1.77B$196.54M-18.92150Earnings ReportAnalyst UpgradeAnalyst RevisionRYTMRhythm Pharmaceuticals3.4803 of 5 stars$90.24+2.2%$91.93+1.9%+108.4%$5.62B$130.13M-32.11140Earnings ReportAnalyst RevisionNUVLNuvalent3.1364 of 5 stars$78.35+0.8%$119.60+52.6%+7.1%$5.58BN/A-17.8540Earnings ReportUpcoming EarningsAnalyst RevisionTGTXTG Therapeutics4.1137 of 5 stars$28.72-18.0%$43.80+52.5%+32.5%$5.56B$329M119.67290Gap DownHigh Trading VolumeAXSMAxsome Therapeutics4.7955 of 5 stars$106.54+3.4%$172.33+61.8%+25.1%$5.07B$385.69M-18.46380LNTHLantheus4.6083 of 5 stars$71.46+1.3%$131.20+83.6%-42.4%$4.88B$1.53B20.30700Earnings ReportAnalyst ForecastCRSPCRISPR Therapeutics3.6947 of 5 stars$59.59+6.2%$70.07+17.6%+17.9%$4.84B$37.31M-13.18460Trending NewsAnalyst RevisionADMAADMA Biologics4.2121 of 5 stars$19.91+3.0%$27.67+39.0%+2.7%$4.61B$426.45M23.42530Earnings ReportABVXAbivax3.258 of 5 stars$72.07+0.2%$92.33+28.1%+516.6%$4.57BN/A0.0061MRUSMerus2.8886 of 5 stars$66.93+2.1%$86.40+29.1%+27.3%$4.54B$36.13M-16.4037Earnings ReportAnalyst RevisionKRYSKrystal Biotech4.7076 of 5 stars$134.94-14.0%$211.33+56.6%-24.5%$4.54B$290.52M32.44210High Trading Volume Related Companies and Tools Related Companies RYTM Competitors NUVL Competitors TGTX Competitors AXSM Competitors LNTH Competitors CRSP Competitors ADMA Competitors ABVX Competitors MRUS Competitors KRYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARQT) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access